gbr 12935

GBR 12935 dihydrochloride (GBR 12935) 是一种多巴胺再吸收抑制剂。

GBR-12935 is a piperazine derivative. It is an effective and selective dopamine reuptake inhibitor. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain.

CM764 is a potent and selective antagonist of sigma-2 receptors, a novel derivative of SN79.

GBR-12935 is a potent and selective dopamine reuptake inhibitor. It was originally developed in its 3H radiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling of dopamine transporter proteins. This has led to potential clinical uses in the diagnosis of Parkinson's disease, although selective radioligands such as Ioflupane (¹²³I) are now available for this application. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain. (Source: http://en.wikipedia.org/wiki/GBR-12935).

SRI-31142 是一种假定的、能够穿透大脑的多巴胺转运蛋白 (DAT) 变构抑制剂。在使用颅内自我刺激 (ICSS) 的行为研究中，SRI-31142 不会表现出可卡因和 GBR-12935 所造成的滥用相关影响，而是在有效剂量条件下降低 ICSS 反应以及伏隔核 (NAc) 中的多巴胺水平。此外，SRI-31142 还能阻止可卡因引发的 ICSS 和 NAc 多巴胺水平上升。